A Prospective, Multicenter, Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Patients Treated With Natalizumab
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 May 2017
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PROTYS
- Sponsors Biogen
- 07 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
- 07 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2018.
- 07 Feb 2017 Status changed from recruiting to active, no longer recruiting.